Pharmexa starts phase I trial in HIV together with HVTN
EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses. The vaccine consists of a string of 18 HIV-derived HTL epitopes, each separated by a spacer designed to optimize potency. The EP-HIV-1090 DNA vaccine encodes 21 HIV-1 derived cytotoxic T-lymphocyte (CTL) epitopes, which are highly conserved amongst viral subtypes. The epitopes in both vaccines were selected using Pharmexa-Epimmune's proprietary Epitope Identification System and each of them is predicted to be recognized in the majority of the prospective patient population.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.